<SEC-DOCUMENT>0001193125-25-122076.txt : 20250519
<SEC-HEADER>0001193125-25-122076.hdr.sgml : 20250519
<ACCEPTANCE-DATETIME>20250519062108
ACCESSION NUMBER:		0001193125-25-122076
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250518
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250519
DATE AS OF CHANGE:		20250519

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Intellia Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001652130
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				364785571
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37766
		FILM NUMBER:		25961436

	BUSINESS ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
		BUSINESS PHONE:		857-285-6200

	MAIL ADDRESS:	
		STREET 1:		40 ERIE STREET
		STREET 2:		SUITE 130
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02139
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d80735d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ntla="http://intelliatx.com/20250518" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-405">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2025-05-18_to_2025-05-18">0001652130</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="ntla-20250518.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2025-05-18_to_2025-05-18"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001652130</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-05-18</xbrli:startDate> <xbrli:endDate>2025-05-18</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">WASHINGTON, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-416">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt:datemonthdayyearen" id="ixv-417">May 18, 2025</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-418">INTELLIA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of Registrant as Specified in Its Charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:stateprovnameen" id="ixv-419">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-420">001-37766</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-421">36-4785571</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or Other Jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of Incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-422">40 Erie Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-423">Suite 130</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-424">Cambridge</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:stateprovnameen" id="ixv-425">Massachusetts</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:center"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-426">02139</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Address of Principal Executive Offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-427">(857)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-428">285-6200</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:boolballotbox" id="ixv-429">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:boolballotbox" id="ixv-430">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:boolballotbox" id="ixv-431">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border-spacing:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:boolballotbox" id="ixv-432">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border-spacing:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br/>on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-433">Common Stock (Par Value $0.0001)</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-434">NTLA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:exchnameen" id="ixv-435">The Nasdaq Global Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#8201;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2025-05-18_to_2025-05-18" format="ixt-sec:boolballotbox" id="ixv-436">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div> <div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;7.01 Regulation FD Disclosure. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2025, Intellia Therapeutics, Inc.&#160;(Intellia or the Company) issued a press release titled &#8220;Intellia Announces Positive <span style="white-space:nowrap">Two-Year</span> <span style="white-space:nowrap">Follow-Up</span> Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran <span style="white-space:nowrap">(nex-z),</span> in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting.&#8221; A copy of the press release is furnished as Exhibit 99.1 to this Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> and is incorporated herein by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished herewith and shall not be deemed &#8220;filed&#8221; for the purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01. Other Events. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&#160;18, 2025, the Company announced positive <span style="white-space:nowrap">two-year</span> <span style="white-space:nowrap">follow-up</span> data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran <span style="white-space:nowrap">(nex-z,</span> also known as NTLA-2001) in patients with transthyretin (ATTR) amyloidosis. <span style="white-space:nowrap">Nex-z</span> is an investigational <span style="font-style:italic">in vivo</span> CRISPR-based gene editing therapy in development as a <span style="white-space:nowrap">one-time</span> treatment for ATTR amyloidosis. The Phase 1 trial is an open-label, <span style="white-space:nowrap">two-part</span> study evaluating the safety and activity of <span style="white-space:nowrap">nex-z</span> in patients with either ATTR amyloidosis with cardiomyopathy <span style="white-space:nowrap">(ATTR-CM)</span> or hereditary ATTR amyloidosis with polyneuropathy <span style="white-space:nowrap">(ATTRv-PN).</span> Development and commercialization of <span style="white-space:nowrap">nex-z</span> is led by the Company as part of a multi-target collaboration with Regeneron Pharmaceuticals, Inc. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline"><span style="white-space:nowrap">ATTR-PN</span> Phase 1 Results</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Across patients who received a <span style="white-space:nowrap">one-time</span> dose of 0.3 mg/kg or higher (n=33), the mean serum TTR reduction by Day 28 was 90% (corresponding mean absolute serum TTR level of 23.8 &#181;g/mL), with levels remaining virtually unchanged for at least 24 months. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In newly reported data, favorable trends indicating stability or improvement were observed in patients with <span style="white-space:nowrap">ATTRv-PN,</span> including six patients previously on patisiran for a mean(sd) of 5.5(1.7) years, who had evidence of disease progression prior to entering the study. Stability or improvement was based on evaluation of multiple clinical and biomarker measures, including Neuropathy Impairment Score (NIS), modified Neuropathy Impairment Score +7 (mNIS+7), modified BMI (mBMI), Norfolk Quality of Life-Diabetic Neuropathy <span style="white-space:nowrap">(QoL-DN)</span> questionnaire and neurofilament light chain (NfL). Among the 18 patients in whom a mNIS+7 assessment was completed at 24 months, 14 out of 18 demonstrated a clinically meaningful improvement of &#8805;4 points as of the April&#160;11, 2025 data cutoff, including 5 of the 6 patients who were previously progressing on patisiran. The clinical and biomarker measure results are detailed in the table below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the table below, a negative change in the data reflects improvement in the NIS, mNIS+7, Norfolk <span style="white-space:nowrap">QoL-DN</span> and NfL results, and a positive change in the data reflects improvement in the mBMI result. The Phase 1 study is ongoing and the reported results reflect the available data as of the data cutoff. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border-spacing:0;margin:0 auto">


<tr>

<td style="width:34%"/>

<td style="vertical-align:bottom"/>
<td style="width:32%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Clinical and Biomarker Measures</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Change from Baseline at Month 12</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Change from Baseline at Month 24</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part 1: Dose-escalation portion (N=15)<sup style="font-size:75%; vertical-align:top">1</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NIS, mean (SD)</p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">-2.0 (5.3)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">-4.5 (7.4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part 2: Dose expansion portion (N=21)<sup style="font-size:75%; vertical-align:top">1</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NIS, mean (SD)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-2.1 (10.2)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-5.2 (10.7)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mNIS+7, mean (SD) (overall)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-0.6 (11.1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-8.5 (9.6)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mNIS+7, mean (SD)</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">(patients previously on patisiran)<sup style="font-size:75%; vertical-align:top">2</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">-6.3 (11.6)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top;white-space:nowrap">-6.5 (9.8)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="5"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Full cohort N=36<sup style="font-size:75%; vertical-align:top">3</sup></p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norfolk <span style="white-space:nowrap">QoL-DN,</span> mean (SD)<sup style="font-size:75%; vertical-align:top">4</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-3.5 (21.0)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-8.5 (19.3)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NfL (% change from baseline)<sup style="font-size:75%; vertical-align:top">5</sup></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">-8.6 (41.7)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">N/A<sup style="font-size:75%; vertical-align:top">6</sup></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mBMI, mean (SD)<sup style="font-size:75%; vertical-align:top">4</sup></p></td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">13.4 (93.2)</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom;white-space:nowrap">39.0 (87.1)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">1</sup> Data cutoff April&#160;11, 2025; <sup style="font-size:75%; vertical-align:top">2</sup> N=6; <sup style="font-size:75%; vertical-align:top">3</sup> <span style="white-space:nowrap">24-month</span> data in 19 patients; <sup style="font-size:75%; vertical-align:top">4</sup> Data cutoff August&#160;21, 2024; <sup style="font-size:75%; vertical-align:top">5</sup> Data cutoff April&#160;12, 2024; </p> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><sup style="font-size:75%; vertical-align:top">6 </sup>N/A: Data not available at Month 24 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">Nex-z</span> has been generally well tolerated as of the data cutoff date across all patients and at all dose levels tested. The most commonly reported treatment-related adverse events were infusion-related reactions, which were mild or moderate, and did not result in any discontinuations. Observed liver enzyme abnormalities were not considered serious, were asymptomatic and resolved spontaneously without medical intervention or sequela. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, the Company noted that enrollment in the Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> study of <span style="white-space:nowrap">nex-z</span> for <span style="white-space:nowrap">ATTRv-PN</span> is progressing well. The <span style="white-space:nowrap">MAGNITUDE-2</span> study is designed to measure clinical outcomes and evaluate how a single dose of <span style="white-space:nowrap">nex-z</span> can lead to reduction in serum TTR, to support a potential BLA submission by 2028. The Company&#8217;s pivotal Phase 3 MAGNITUDE study of <span style="white-space:nowrap">nex-z</span> for <span style="white-space:nowrap">ATTR-CM</span> is currently enrolling, and the Company anticipates enrollment completion by early 2027. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Forward-Looking Statements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report <span style="white-space:nowrap">on&#160;Form&#160;8-K&#160;and&#160;certain</span> of the materials furnished or filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. The words &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#8217;s beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or <span style="white-space:nowrap">&#8220;nex-z&#8221;</span> (also known as NTLA-2001) for transthyretin (ATTR) amyloidosis, including the ability to successfully complete its global Phase 3 <span style="white-space:nowrap">MAGNITUDE-2</span> study for hereditary ATTR amyloidosis with polyneuropathy <span style="white-space:nowrap">(ATTRv-PN)</span> pursuant to its clinical trial applications and investigational new drug submissions; its belief that enrollment continues to progress well in the <span style="white-space:nowrap">MAGNITUDE-2</span> study; its expectation to be able to support a potential biologics license application submission for <span style="white-space:nowrap">nex-z</span> for the treatment of <span style="white-space:nowrap">ATTRv-PN</span> by 2028; and its expectation to be able to complete enrollment of the pivotal Phase 3 MAGNITUDE study for ATTR amyloidosis with cardiomyopathy by early 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this current report on <span style="white-space:nowrap">Form&#160;8-K&#160;are</span> based on management&#8217;s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia&#8217;s ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#8217;s relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies&#8217; evaluation of regulatory filings and other information related to our product candidates, including <span style="white-space:nowrap">nex-z;</span> uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to enroll and complete our clinical trials; the risk that any one or more of Intellia&#8217;s product candidates, including <span style="white-space:nowrap">nex-z,</span> will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#8217;s other product candidates; and risks related to Intellia&#8217;s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia&#8217;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#8220;Risk Factors&#8221; in Intellia&#8217;s most recent annual report on <span style="white-space:nowrap">Form&#160;10-K</span> and quarterly report on Form <span style="white-space:nowrap">10-Q,</span> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#8217;s other filings with the Securities and Exchange Commission. All information in this current report on Form <span style="white-space:nowrap">8-K</span> is as of the date of the report, and Intellia undertakes no duty to update this information unless required by law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center">Exhibit<br/>No.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d80735dex991.htm">Press release dated May&#160;18, 2025. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border-spacing:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Intellia Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: May&#160;19, 2025</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ John M. Leonard</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Name: John M. Leonard</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Title: Chief Executive Officer and President</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d80735dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80735g89s41.jpg" ALT="LOGO" STYLE="width:1.59583in;height:0.636111in;">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g80735g23w83.jpg" ALT="LOGO" STYLE="width:7.37917in;height:0.264583in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Intellia Announces Positive <FONT STYLE="white-space:nowrap">Two-Year</FONT> <FONT
STYLE="white-space:nowrap">Follow-Up</FONT> Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Deep, durable and consistent reductions in TTR were sustained at two years, following a <FONT
STYLE="white-space:nowrap">one-time</FONT> dose of nex-z</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Clinically meaningful improvements in ATTRv-PN related outcomes observed at 24 months compared to baseline,
including in patients who were previously progressing on patisiran</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Continue to observe generally favorable safety and tolerability data in the full Phase 1 cohort with no new
drug-related adverse events within the <FONT STYLE="white-space:nowrap">follow-up</FONT> period</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Enrollment continues to progress well in <FONT STYLE="white-space:nowrap">MAGNITUDE-2,</FONT> which is
designed to measure clinical outcomes (including mNIS+7) and evaluate how a single dose of nex-z can lead to reduction in serum TTR, to potentially support a BLA submission by 2028</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CAMBRIDGE, Mass., May&nbsp;18, 2025 (GLOBE NEWSWIRE) &#151; Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused
on revolutionizing medicine with CRISPR-based therapies, today announced positive <FONT STYLE="white-space:nowrap">two-year</FONT> <FONT STYLE="white-space:nowrap">follow-up</FONT> data from the ongoing Phase 1 trial of investigational nexiguran
ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May&nbsp;18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United
Kingdom. The Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are pleased to share new findings at PNS, which continue to support our growing body of evidence that a single dose of nex-z leads to deep, durable
and consistent reductions in serum TTRs, with evidence of disease stability or clinically meaningful improvements in neuropathic impairment measures through two years,&#148; said Intellia President and Chief Executive Officer John Leonard, M.D.
&#147;These data are also the first to show improvement in patients who had previously progressed on patisiran, further validating the hypothesis that increasingly deep reductions in TTR levels may lead to improved outcomes in ATTR
amyloidosis.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 1 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ATTRv-PN Results </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Rapid, Deep and Durable Serum TTR Reduction: </B>Across patients who received a
<FONT STYLE="white-space:nowrap">one-time</FONT> dose of 0.3 mg/kg or higher (n=33),<B> </B>the mean serum TTR reduction by Day 28 was 90% (corresponding mean absolute serum TTR level of 23.8 &micro;g/mL), with levels remaining virtually unchanged
for at least 24 months. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Evidence of Disease Modification on Clinical and Biomarker Measures:</B> Favorable trends indicating stability
or improvement were observed in patients with ATTRv-PN, including six patients previously on patisiran for a mean(sd) of 5.5(1.7) years, who had evidence of disease progression prior to entering the study. Stability or improvement was based on
evaluation of multiple clinical and biomarker measures, including Neuropathy Impairment Score (NIS), modified Neuropathy Impairment Score +7 (mNIS+7), modified BMI (mBMI), Norfolk Quality of Life-Diabetic Neuropathy (QoL-DN) questionnaire and
neurofilament light chain (NfL). Among the 18 patients in whom a mNIS+7 assessment was completed at 24 months, 14 out of 18 demonstrated a clinically meaningful improvement of &#8805;4 points as of the April&nbsp;11, 2025 data cutoff, including 5 of
the 6 patients who were previously progressing on patisiran. The clinical and biomarker measure results are detailed in the table below. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="59%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Clinical and Biomarker Measures</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;from&nbsp;Baseline<BR>at Month 12</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change&nbsp;from&nbsp;Baseline<BR>at Month 24</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part 1: Dose-escalation portion N=15*</B></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NIS, mean (SD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-2.0&nbsp;(5.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-4.5&nbsp;(7.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Part 2: Dose expansion portion N=21*</B></P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NIS, mean (SD)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-2.1&nbsp;(10.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-5.2&nbsp;(10.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mNIS+7, mean (SD) (overall)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-0.6&nbsp;(11.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-8.5&nbsp;(9.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mNIS+7, mean (SD) (patients previously on
patisiran)<SUP STYLE="font-size:75%; vertical-align:top"> </SUP><SUP STYLE="font-size:75%; vertical-align:top"><FONT STYLE="font-size:6.5pt">&#134;</FONT></SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-6.3&nbsp;(11.6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-6.5&nbsp;(9.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="8"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>Full cohort N=36</B>&#135;</P></TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:10pt; font-family:Times New Roman"><B></B>&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Norfolk QoL-DN, mean (SD)**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-3.5&nbsp;(21.0</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-8.5&nbsp;(19.3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">NfL (% change from baseline)***</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">-8.6&nbsp;(41.7</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">N/A</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">mBMI, mean (SD)**</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13.4&nbsp;(93.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">39.0&nbsp;(87.1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Data cutoff April&nbsp;11, 2025; ** Data cutoff August&nbsp;21, 2024; *** Data cutoff April&nbsp;12, 2024; <SUP
STYLE="font-size:75%; vertical-align:top"><FONT STYLE="font-size:6.5pt">&#134;</FONT></SUP>N=6; &#135; <FONT STYLE="white-space:nowrap">24-month</FONT> data in 19 patients; N/A: Data not available at Month 24 </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Negative change reflects improvement in the following results: NIS, mNIS+7, Norfolk QoL-DN and NfL </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Positive change reflects improvement in mBMI </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:10pt; font-family:Times New Roman">Study is ongoing and reported results reflect the available data as of the data cutoff </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 2 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><B>Safety: </B>Nex-z has been generally well tolerated as of the data cutoff date across all patients and at all
dose levels tested. The most commonly reported treatment-related adverse events were infusion-related reactions, which were mild or moderate, and did not result in any discontinuations. Observed liver enzyme abnormalities were not considered
serious, were asymptomatic and resolved spontaneously without medical intervention or sequela. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The presentation will be available on
the Scientific Publications&nbsp;&amp; Presentations section of intelliatx.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the </B><B>Nexiguran</B><B> </B><B>Ziclumeran</B><B>
(</B><B>nex</B><B>-z, also known as NTLA-2001)</B><B> Clinical Program </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The global Phase 1 trial is an ongoing open-label, multi-center, <FONT
STYLE="white-space:nowrap">two-part</FONT> study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) or transthyretin amyloidosis with cardiomyopathy <FONT STYLE="white-space:nowrap">(ATTR-CM).</FONT> Part
1 of the ATTRv-PN arm of the study is an open-label, single-ascending dose escalation cohort and Part 2 is an open-label, single-dose expansion cohort. Visit clinicaltrials.gov (NCT04601051) for more details. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> Study </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The pivotal Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the
efficacy and safety of nexiguran ziclumeran <FONT STYLE="white-space:nowrap">(nex-z)</FONT> in approximately 50 patients with hereditary transthyretin amyloidosis with polyneuropathy <FONT STYLE="white-space:nowrap">(ATTRv-PN).</FONT> The primary
endpoints of the study are a change in a modified neuropathy impairment score and a change in serum TTR levels. Adult patients with <FONT STYLE="white-space:nowrap">ATTRv-PN</FONT> will be randomized 1:1 to receive a single 55 mg infusion of <FONT
STYLE="white-space:nowrap">nex-z</FONT> or placebo. For more information on <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> (NCT06672237), please visit&nbsp;clinicaltrials.gov. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About</B><B></B><B>&nbsp;Nex-z </B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on Nobel <FONT
STYLE="white-space:nowrap">Prize-winning</FONT> CRISPR/Cas9 gene editing technology, <FONT STYLE="white-space:nowrap">nex-z</FONT> has the potential to become the first <FONT STYLE="white-space:nowrap">one-time</FONT> treatment for transthyretin
(ATTR) amyloidosis. <FONT STYLE="white-space:nowrap">Nex-z</FONT> is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of
<FONT STYLE="white-space:nowrap">nex-z</FONT> led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of <FONT STYLE="white-space:nowrap">nex-z</FONT> as part of a multi-target discovery, development
and commercialization collaboration with Regeneron Pharmaceuticals, Inc. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 3 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Transthyretin (ATTR) Amyloidosis </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease. Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with
mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious complications in multiple tissues,
including the heart, nerves and digestive system. ATTRv amyloidosis predominantly manifests as polyneuropathy <FONT STYLE="white-space:nowrap">(ATTRv-PN),</FONT> which can lead to nerve damage, or cardiomyopathy
<FONT STYLE="white-space:nowrap">(ATTRv-CM),</FONT> which can lead to heart failure. Some individuals without the genetic mutation produce <FONT STYLE="white-space:nowrap">non-mutated,</FONT> or wild-type TTR proteins that become unstable over time,
misfolding and aggregating in disease-causing amyloid deposits. This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000
and 500,000 people with ATTRwt amyloidosis. There is no known cure for ATTR amyloidosis and currently available medications are limited to slowing accumulation of misfolded TTR protein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Intellia Therapeutics </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Intellia Therapeutics,
Inc.&nbsp;(NASDAQ: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia&#146;s deep scientific, technical and clinical
development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and
delivery technologies. Learn more at&nbsp;intelliatx.com&nbsp;and follow us&nbsp;@intelliatx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains &#147;forward-looking statements&#148; of Intellia Therapeutics, Inc. (&#147;Intellia&#148; or the &#147;Company&#148;) within the
meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia&#146;s beliefs and expectations regarding: the safety, tolerability,
efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or &#147;nex-z&#148; (also known as NTLA-2001) for transthyretin (&#147;ATTR&#148;) amyloidosis, including the ability to successfully complete its global Phase 3 <FONT
STYLE="white-space:nowrap">MAGNITUDE-2</FONT> study for hereditary ATTR amyloidosis with polyneuropathy (&#147;ATTRv-PN&#148;) pursuant to its clinical trial applications and investigational new drug submissions; its belief that enrollment continues
to progress well in the <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> study; its belief that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTR and that increasingly deep reductions in TTR levels leads to
improved outcomes; and its expectation to be able to support the submission of a biologics license application for nex-z for the treatment of ATTRv-PN by 2028. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any forward-looking statements in this press release are based on management&#146;s current expectations and beliefs of future events and are subject to a
number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related
to Intellia&#146;s ability to protect and maintain its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 4 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
intellectual property position; risks related to valid third party intellectual property; risks related to Intellia&#146;s relationship with third parties, including its licensors and licensees;
risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies&#146; evaluation of regulatory filings and other information related to our product candidates,
including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials,
including our ability to enroll the Phase 3 <FONT STYLE="white-space:nowrap">MAGNITUDE-2</FONT> study for ATTRv-PN; the risk that any one or more of Intellia&#146;s product candidates, including nex-z, will not be successfully developed and
commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia&#146;s other product candidates; and risks
related to Intellia&#146;s reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other
important factors, any of which could cause Intellia&#146;s actual results to differ from those contained in the forward-looking statements, see the section entitled &#147;Risk Factors&#148; in Intellia&#146;s most recent annual report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> and quarterly report on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as discussions of potential risks, uncertainties, and other important factors in Intellia&#146;s other filings with the
Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Intellia Contacts: </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brittany Chaves </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Senior Manager, Investor Relations </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">brittany.chaves@intelliatx.com </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media: </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matt Crenson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ten Bridge Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">media@intelliatx.com </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">mcrenson@tenbridgecommunications.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Page 5 of 5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">intelliatx.com</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ntla-20250518.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/19/2025 9:05:34 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2024"
  xmlns:ntla="http://intelliatx.com/20250518"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://intelliatx.com/20250518"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" namespace="http://xbrl.sec.gov/naics/2024" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20250518_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ntla-20250518_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>ntla-20250518_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/19/2025 9:05:34 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>ntla-20250518_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20241122.1 -->
<!-- Creation date: 5/19/2025 9:05:35 AM Eastern Time -->
<!-- Copyright (c) 2025 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="ntla-20250518.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g80735g23w83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80735g23w83.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M1O%O_84/_HB"O8P_\&GZ?JSP,5_O%7U_1'KW[6G_ ":]K7_7'P+_ .G[0Z^
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M'W1\(_\ DC*_]>OB?_TJU"O+Q'^\/_MW\D>UA?\ =%Z3_-GF/[,W_(:\4?\
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MJ%:I"AB?9RI>WI1DU"K[.5Y0YXI2Y):QO9ZH^*M)\+_&+]F_4O&Q\-^"M/\
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M'YL>(?\ D/ZY_P!AC4__ $MGKV8?!#_"OR/GJG\2?^)_F?7/[-7_ "*>N_\
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M/$-G#:)J$&FI:F&\MKK>UM)>M*&%O(VS FC^]C.>.E98FM"HH<C^&]]+=O\
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M)\TH8FI)?NZ4E&T'>5D[)MK]*Z_23^9@H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g80735g89s41.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g80735g89s41.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MXKX2IX6KQ%E<<NI8R4X4&L5A<1SRIJ,IJV'K57'E4HN\DD[Z7LSVNO3/E@H
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M^%+_ !/\HGCYA_&C_@7_ *5(^FOA7_R3OPC_ -@>#_T.2N&O_&J?XF>CAO\
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MC/\ =JG_ &[_ .E1/'?V8_\ C]\8?]>NB_\ HW4JZ,;M3_[>_0Y<MWJ^D?\
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M-O[^1_F>H?$:6R7P=YEWJ.IZ+:F?3B+K1=0M=)NXBQS'#'=7CQQI$WW2A()
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ME_B?Y1,<P_C1_P "_P#2I'TU\*_^2=^$?^P/!_Z')7#7_C5/\3/1PW^[TO\
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#M__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>May 18, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001652130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 18,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">INTELLIA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">36-4785571<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">40 Erie Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 130<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">285-6200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock (Par Value $0.0001)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NTLA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d80735d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d80735d8k.htm">d80735d8k.htm</File>
    <File>ntla-20250518.xsd</File>
    <File>ntla-20250518_lab.xml</File>
    <File>ntla-20250518_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d80735d8k.htm": {
   "nsprefix": "ntla",
   "nsuri": "http://intelliatx.com/20250518",
   "dts": {
    "inline": {
     "local": [
      "d80735d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "ntla-20250518.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "ntla-20250518_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ntla-20250518_pre.xml"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 23
   },
   "report": {
    "R1": {
     "role": "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2025-05-18_to_2025-05-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d80735d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2025-05-18_to_2025-05-18",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d80735d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://intelliatx.com//20250518/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001193125-25-122076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-122076-xbrl.zip
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M1)<FHNBD(=VP7Q/#H*/O7T6O3/0)#A$P'N$A8''K!MF1:8J!CX-[N&J,^+8
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MX?[K(%*QNI/BX.-5ZS:=05_%LAP-+%ON^<%]: U6CF[O@_*?T@H/UO'.(_W
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MF?/0!A4CQ6KKO W*PJ-=@S=.N_<?VV)5!X=R3YQ<GL-E^"]<; 5A-W"_BM]
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M*SQ0WPA%0]#B"4?,3%QHFCUBI6GA1W#O(BQ%QNYW*NH&+H?%J(^1!SSKF&>
MW 3#6,D %;F>GJ$66T>5B$:J(N>X$]<3F\@+'<V8ZNQ815$BHT+[5&I@),%
ME  ZAW<RTD&R'I8_P^)'0S!G7H7=WL+Z#F + -[ZEA]C&;+EJRX\0V7&3W<#
M1EH%YKOX$7EZ?8B!BJ[]'!9;OP:<^RFOH<4 ?E-N$@*GM1$Z8>'_G7(2,&UI
MH X7#ED%XWJ&CU+>F&VB [],3X%7F(/RX#HXY7@X8$Y,>8"0CX9QB1]Q171
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M;4/KJ&0G)%6)"X=O=X@=COE-BVA&%<8+DRG.;DX]5C(K+,ZF-UEH5*H45#O
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M#]B'7M=G[#_[""<>^0=02P$"% ,4    " "C,K-:"^P;J" =   :J@  #0
M            @ $     9#@P-S,U9#AK+FAT;5!+ 0(4 Q0    ( *,RLUH9
M]-70 1H  #B"   0              "  4L=  !D.# W,S5D97@Y.3$N:'1M
M4$L! A0#%     @ HS*S6MX&$BL_ P  1@L  !$              ( !>C<
M &YT;&$M,C R-3 U,3@N>'-D4$L! A0#%     @ HS*S6BI"&:E[!@  N48
M !4              ( !Z#H  &YT;&$M,C R-3 U,3A?;&%B+GAM;%!+ 0(4
M Q0    ( *,RLUJS8**6P@0  #LL   5              "  99!  !N=&QA
G+3(P,C4P-3$X7W!R92YX;6Q02P4&      4 !0 ^ 0  BT8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>d80735d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ntla-20250518.xsd" xlink:type="simple"/>
    <context id="duration_2025-05-18_to_2025-05-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001652130</identifier>
        </entity>
        <period>
            <startDate>2025-05-18</startDate>
            <endDate>2025-05-18</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-405">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2025-05-18_to_2025-05-18"
      id="Hidden_dei_EntityCentralIndexKey">0001652130</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-416">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-417">2025-05-18</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-418">INTELLIA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-419">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-420">001-37766</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-421">36-4785571</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-422">40 Erie Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-423">Suite 130</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-424">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-425">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-426">02139</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-427">(857)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-428">285-6200</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-429">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-430">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-431">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-432">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-433">Common Stock (Par Value $0.0001)</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-434">NTLA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-435">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2025-05-18_to_2025-05-18" id="ixv-436">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
